Show simple item record

dc.contributor.authorCrabtree, T
dc.contributor.authorTaylor, Nick
dc.contributor.authorLangeland, L
dc.contributor.authorWilmot, Emma
dc.contributor.authorIdris, Iskandar
dc.date.accessioned2022-01-25T14:56:39Z
dc.date.available2022-01-25T14:56:39Z
dc.identifier.citationDiabet Med. 2022 Jan 16:e14793. doi: 10.1111/dme.14793. Online ahead of print.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15103
dc.description.abstractThe use of do-it-yourself artificial pancreas systems (DIYAPS) amongst people with type 1 diabetes is increasing. At present, it is unclear DIYAPS comepares to other technologies such as FreeStyle Libre (FSL) and continuous subcutaneous insulin infusion (CSII). The aim of this analysis is to compare safety, effectiveness and quality of life outcomes of DIYAPS use with the addition of FSL to CSII. METHOD: Data from two large UK hospitals were extracted from the Association of British Clinical Diabetologists (ABCD) DIYAPS and FSL audits. Outcomes included HbA1c, glucose TBR (time-below-range), TIR (time-in-range), Diabetes Distress Scores (DDS) and Gold hypoglycaemia Score. Any adverse events were noted. Changes at follow-up were assessed using paired t-tests and ANOVA in Stata; TIR/TBR at follow-up assessed using unpaired T-Tests; Chi-square tests assessed the change in frequency of health utilisation (e.g. hospital admissions). RESULTS: DIYAPS (n=35) and FSL+CSII (n=149) users, with median follow-up duration of 1.4 (IQR 0.8-2.1) and 1.3 (IQR 0.7-1.8) years respectively, were included. HbA1c with DIYAPS use changed by -10mmol/mol [0.9%] (p<0.001, 95% CI 5, 14 [0.5, 1.3%]) significantly lower (p<0.001) than in the FSL+CSII group -3 mmol/mol [0.25%] (p<0.001, 95% CI 1, 4 [0.1, 0.4%]). TIR was higher and TBR was lower in the DIYAPS group. Adverse events were rare in both groups and no significant differences were observed in the frequency of healthcare utilisation. CONCLUSION: DIYAPS use was associated with a lower HbA1c levels, higher TIR and lower TBR compared to FSL+CSII. There was no significant increase in adverse events, although this should be interpreted cautiously given the low numbers of users. Full results from the ABCD DIYAPS audit are awaited.
dc.subjectDo It Your Self Artificial Pancreas system (DIYAPS)en_US
dc.subjectType I Diabetesen_US
dc.subjectFreestyle Libreen_US
dc.subjectContinuous Subcutaneous Insulin Infusionen_US
dc.titleSafety and effectiveness of Do-It-Yourself Artificial Pancreas System (DIYAPS) compared with continuous subcutaneous insulin infusions (CSII) in combination with Free Style Libre (FSL) in people with Type 1 diabetes.en_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecorddoi: 10.1111/dme.14793en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2022-01
html.description.abstractThe use of do-it-yourself artificial pancreas systems (DIYAPS) amongst people with type 1 diabetes is increasing. At present, it is unclear DIYAPS comepares to other technologies such as FreeStyle Libre (FSL) and continuous subcutaneous insulin infusion (CSII). The aim of this analysis is to compare safety, effectiveness and quality of life outcomes of DIYAPS use with the addition of FSL to CSII. METHOD: Data from two large UK hospitals were extracted from the Association of British Clinical Diabetologists (ABCD) DIYAPS and FSL audits. Outcomes included HbA1c, glucose TBR (time-below-range), TIR (time-in-range), Diabetes Distress Scores (DDS) and Gold hypoglycaemia Score. Any adverse events were noted. Changes at follow-up were assessed using paired t-tests and ANOVA in Stata; TIR/TBR at follow-up assessed using unpaired T-Tests; Chi-square tests assessed the change in frequency of health utilisation (e.g. hospital admissions). RESULTS: DIYAPS (n=35) and FSL+CSII (n=149) users, with median follow-up duration of 1.4 (IQR 0.8-2.1) and 1.3 (IQR 0.7-1.8) years respectively, were included. HbA1c with DIYAPS use changed by -10mmol/mol [0.9%] (p<0.001, 95% CI 5, 14 [0.5, 1.3%]) significantly lower (p<0.001) than in the FSL+CSII group -3 mmol/mol [0.25%] (p<0.001, 95% CI 1, 4 [0.1, 0.4%]). TIR was higher and TBR was lower in the DIYAPS group. Adverse events were rare in both groups and no significant differences were observed in the frequency of healthcare utilisation. CONCLUSION: DIYAPS use was associated with a lower HbA1c levels, higher TIR and lower TBR compared to FSL+CSII. There was no significant increase in adverse events, although this should be interpreted cautiously given the low numbers of users. Full results from the ABCD DIYAPS audit are awaited.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record